Cystic Fibrosis Market Research Report Information By Treatment Method (Medication and Devices), By Route of Administration (Oral and Inhaled), By Drug Class (Pancreatic Enzyme Supplements, Mucolytic, Bronchodilators, Antibiotics and CFTR modulators), and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2032

1 Introduction

1.1 Definition 8

1.2 Scope of Study 8

1.3 Research Objective 8

1.4 Assumptions & Limitations 9

1.4.1 Assumptions 9

1.4.2 Limitations 9

1.5 Market Structure 9

2 Research Methodology

2.1 Research Process 10

2.2 Primary Research 11

2.3 Secondary Research 11

3 Market Dynamics

3.1 Drivers 12

3.1.1 Introduction 12

3.1.2 Development of New Drugs and Therapies 12

3.1.3 Financial Support from CFF in Research & Development of CF Drugs. 12

3.2 Restraints 13

3.2.1 Introduction 13

3.2.2 High Cost of the Drugs and Treatment 13

3.3 Opportunities 13

3.4 Challenges 14

3.4.1 Awareness About the Rare Disease in the Developing Countries 14

4 Market Factor Analysis

4.1 Porter’s Five Forces Model 15

4.1.1 Bargaining Power of Suppliers 15

4.1.2 Bargaining Power of Buyers 15

4.1.3 Threat of New Entrants 16

4.1.4 Threat of Substitutes 16

4.1.5 Intensity of Rivalry 16

5 Cystic Fibrosis Market, By Treatment Method

5.1 Introduction 17

5.2 Medication 18

5.3 Devices 19

5.4 Other Treatments 20

6 Cystic Fibrosis Market, By Regions

6.1 Introduction 22

6.2 North America 24

Cystic Fibrosis Market, By Treatment Method

Cystic Fibrosis Market, By Regions

6.3 Europe 27

Cystic Fibrosis Market, By Treatment Method

Cystic Fibrosis Market, By Regions

6.4 Asia–Pacific 33

Cystic Fibrosis Market, By Treatment Method

Cystic Fibrosis Market, By Regions

6.5 Middle East & Africa 38

Cystic Fibrosis Market, By Treatment Method

Cystic Fibrosis Market, By Regions

7 Company Share Analysis

8 Company Profile

8.1 AbbVie 43

8.1.1 Company Overview 43

8.1.2 Product Overview 43

8.1.3 Financials 44

8.1.4 Key Developments 44.

8.2 Allergan PLC 46

8.2.1 Company Overview 46

8.2.2 Product Overview 46

8.2.3 Financials 46

8.2.4 Key Developments 46.

8.3 Chiesi Farmaceutici SpA 48

8.3.1 Company Overview 48

8.3.2 Product/Business Segment Overview 48

8.3.3 Financials 48

8.3.4 Key Developments 49

8.4 F. Hoffmann–La Roche AG 50

8.4.1 Company Overview 50

8.4.2 Product/Business Segment Overview 50

8.4.3 Financials 50

8.4.4 Key Developments 51

8.5 Gilead Sciences 52

8.5.1 Company Overview 52

8.5.2 Product Overview 52

8.5.3 Financials 52

8.5.4 Key Developments 52

8.6 Novartis AG 53

8.6.1 Company Overview 53

8.6.2 Product Overview 53

8.6.3 Financials 53

8.6.4 Key Developments 54

8.7 Pharmaxis Ltd 55

8.7.1 Company Overview 55

8.7.2 Product Overview 55

8.7.3 Financials 55

8.7.4 Key Developments 56

8.8 PTC Therapeutics 57

8.8.1 Company Overview 57

8.8.2 Product Overview 57

8.8.3 Financials 57

8.8.4 Key Developments 58

8.9 Vertex Pharmaceuticals Incorporated 59

8.9.1 Company Overview 59

8.9.2 Product/Business Segment Overview 59

8.9.3 Financials 59

9 List of Tables

TABLE 1 GLOBAL CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 18

TABLE 2 GLOBAL CYSTIC FIBROSIS MEDICATION MARKET, BY REGION, 2020–2027 ($MILLION) 19

TABLE 3 GLOBAL CYSTIC FIBROSIS DEVICES MARKET, BY REGION, 2020–2027 ($MILLION) 20

TABLE 4 GLOBAL CYSTIC FIBROSIS OTHER TREATMENTS MARKET, BY REGION, 2020–2027 ($MILLION) 21

TABLE 5 GLOBAL CYSTIC FIBROSIS MARKET, BY REGION, 2020–2027 ($MILLION) 23

TABLE 6 NORTH AMERICA CYSTIC FIBROSIS MARKET, BY COUNTRY, 2020–2027 ($MILLION) 24

TABLE 7 NORTH AMERICA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 25

TABLE 8 US CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 26

TABLE 9 CANADA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 26

TABLE 10 EUROPE CYSTIC FIBROSIS MARKET, BY COUNTRY, 2020–2027 ($MILLION) 28

TABLE 11 EUROPE CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 29

TABLE 12 GERMANY CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 29

TABLE 13 FRANCE CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 29

TABLE 14 UK CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 30

TABLE 15 ITALY CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 30

TABLE 16 SPAIN CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 31

TABLE 17 REST OF WESTERN EUROPE CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 31

TABLE 18 EASTERN EUROPE CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 32

TABLE 19 ASIA-PACIFIC CYSTIC FIBROSIS MARKET, BY COUNTRY, 2020–2027 ($MILLION) 34

TABLE 20 ASIA-PACIFIC CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 35

TABLE 21 AUSTRALIA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 35

TABLE 22 JAPAN CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 35

TABLE 23 CHINA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 36

TABLE 24 INDIA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 36

TABLE 25 REPUBLIC OF KOREA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 37

TABLE 26 REST OF ASIA-PACIFIC CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 37

TABLE 27 MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET, BY REGION, 2020–2027 ($MILLION) 38

TABLE 28 MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 39

TABLE 29 MIDDLE EAST CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 40

TABLE 30 AFRICA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020–2027 ($MILLION) 40

TABLE 31 CHIESI FARMACEUTICI SPA: KEY DEVELOPMENTS 49

TABLE 32 VERTEX PHARMACEUTICALS INCORPORATED: KEY DEVELOPMENTS 60

10 List of Figures

FIGURE 1 RESEARCH PROCESS OF MRFR 10

FIGURE 2 PORTER'S 5 FORCES ANALYSIS OF GLOBAL CYSTIC FIBROSIS MARKET 15

FIGURE 3 GLOBAL CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020 & 2027 ($MILLION) 17

FIGURE 4 GLOBAL CYSTIC FIBROSIS MARKET, BY REGION, 2020 (%) 22

FIGURE 5 NORTH AMERICA CYSTIC FIBROSIS MARKET, BY COUNTRY, 2020 (%) 24

FIGURE 6 NORTH AMERICA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020 & 2027 ($MILLION) 25

FIGURE 7 EUROPE CYSTIC FIBROSIS MARKET, BY COUNTRY, 2020 (%) 27

FIGURE 8 EUROPE CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020 & 2027 ($MILLION) 28

FIGURE 9 ASIA-PACIFIC CYSTIC FIBROSIS MARKET, BY COUNTRY, 2020 (%) 33

FIGURE 10 ASIA-PACIFIC CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020 % 2027 ($MILLION) 34

FIGURE 11 MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET, BY REGION, 2020 (%) 38

FIGURE 12 MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2020 & 2027 ($MILLION) 39

FIGURE 13 CYSTIC FINROSIS MARKET SHARE, 2020 (%) 41

FIGURE 14 ABBVIE: RECENT FINANCIAL 44

FIGURE 15 ABBVIE: BUSINESS REVENUE, 2020 (%) 44

FIGURE 16 ABBVIE: GEOGRAPHIC REVENUE, 2020 (%) 45

FIGURE 17 ALLERGAN: RECENT FINANCIAL 46

FIGURE 18 ALLERGAN: BUSINESS REVENUE, 2020 (%) 47

FIGURE 19 ALLERGAN: GEOGRAPHIC REVENUE, 2020 (%) 47

FIGURE 20 CHIESI FARMACEUTICI S.P.A.: RECENT FINANCIALS 48

FIGURE 21 F. HOFFMANN-LA ROCHE AG.: RECENT FINANCIALS 50

FIGURE 22 F. HOFFMANN-LA ROCHE AG.: BUSINESS REVENUE 51

FIGURE 23 GILEAD SCIENCES: RECENT FINANCIAL 52

FIGURE 24 NOVARTIS AG: RECENT FINANCIALS 53

FIGURE 25 NOVARTIS AG: BUSINESS REVENUE, 2020 (%) 54

FIGURE 26 NOVARTIS AG: GEOGRAPHIC REVENUE, 2020 (%) 54

FIGURE 27 PHARMAXIS LTD: RECENT FINANCIALS 55

FIGURE 28 PTC THERAPEUTICS: RECENT FINANCIALS 57

FIGURE 29 PTC THERAPEUTICS: GEOGRAPHICAL REVENUE (%) 58

FIGURE 30 PTC THERAPEUTICS: R&D EXPENSES, 2020 (%) 58

FIGURE 31 VERTEX PHARMACEUTICALS INCORPORATED: RECENT FINANCIALS 59

FIGURE 32 VERTEX PHARMACEUTICALS INCORPORATED: BUSINESS REVENUE 60

FIGURE 33 VERTEX PHARMACEUTICALS INCORPORATED: GEOGRAPHICAL REVENUE 60